Table 1.
Baseline characteristics of the full HBV-HIV analysis sample and paried biopsy subsample, overall and stratified by HBeAg status
| Full analysis sample |
Biopsy subsample |
|||||
|---|---|---|---|---|---|---|
| Total n=95 | HBeAg positive n=58 | HBeAg negative n=37 | Total n=56 | HBeAg positive n=33 | HBeAg negative n=23 | |
| Age (years) | ||||||
| Median (25th, 75th) | 50 (46, 55) | 49.5 (45, 54) | 51 (47, 56) | 50.5 (46, 54) | 49 (46, 54) | 52 (48, 56) |
| Male, n (%) | 88 (92.6) | 51 (87.9) | 37 (100.0) | 53 (94.6) | 30 (90.9) | 23 (100.0) |
| Race, n (%) | n=93 | n=57 | n=36 | n=54 | n=32 | n=22 |
| Non-Hispanic White | 32 (34.4) | 21 (36.8) | 11 (30.6) | 15 (27.8) | 10 (31.3) | 5 (22.7) |
| Non-Hispanic Black | 45 (48.4) | 25 (43.9) | 20 (55.6) | 28 (51.9) | 16 (50.0) | 12 (54.5) |
| Non-Hispanic Asian | 5 (5.4) | 2 (3.5) | 3 (8.3) | 4 (7.4) | 1 (3.1) | 3 (13.6) |
| Other | 11 (11.8) | 9 (15.8) | 2 (5.6) | 7 (13.0) | 5 (15.6) | 2 (9.1) |
| Body mass index (kg/m2) | n=92 | n=56 | n=36 | n=54 | n=32 | n=22 |
| Median (25th, 75th) | 25.8 (22.6, 30.0) | 26.6 (22.5, 31.6) | 25.2 (22.6, 27.3) | 25.8 (22.8, 29.3) | 25.8 (22.2, 30.0) | 25.9 (23.3, 27.1) |
| Estimated years of HBV or HIV | n=89 | n=53 | n=36 | n=51 | n=29 | n=22 |
| Median (25th, 75th) | 21 (15, 28) | 22 (16, 26) | 20 (11.5, 30) | 22 (15, 28) | 21 (16, 25) | 22.5 (15, 30) |
| HBV treatment, n (%) | ||||||
| Tenofovir alone/combination | 84 (88.4) | 52 (89.7) | 32 (86.5) | 51 (91.0) | 31 (93.9) | 20 (87.0) |
| Entecavir alone/combination | 8 (8.5) | 4 (6.8) | 4 (10.8) | 5 (9.0) | 2 (6.1) | 3 (13.0) |
| Lamivudine alone | 1 (1.1) | 1 (1.7) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
| None | 2 (2.1) | 1 (1.7) | 1 (2.7) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
| Nucleoside/Nucleotide Reverse Transcriptase Inhibitor use, n (%) | 91 (95.8) | 55 (94.8) | 36 (97.3) | 54 (96.4) | 32 (97.0) | 22 (95.7) |
| ALT (U/L) | n=91 | n=56 | n=35 | n=55 | n=22 | |
| Median (25th, 75th) | 24 (18, 39) | 24 (17, 42.5) | 27 (19, 37) | 24 (18, 36) | 24 (18, 34) | 26.5 (19, 36) |
| AST (U/L) | n=91 | n=56 | n=35 | n=55 | n=22 | |
| Median (25th, 75th) | 28 (22, 41) | 27 (22, 38) | 29 (22, 45) | 27 (21,41) | 27 (22, 32) | 28.5 (21,48) |
| Total Bilirubin (mg/dL) | n=90 | n=55 | n=35 | n=54 | n=32 | n=22 |
| Median (25th, 75th) | 0.5 (0.3, 0.7) | 0.5 (0.3, 0.8) | 0.5 (0.3, 0.6) | 0.5 (0.3, 0.7) | 0.5 (0.3, 0.8) | 0.5 (0.3, 0.7) |
| Albumin (g/dL) | n=91 | n=56 | n=35 | n=55 | n=22 | |
| Median (25th, 75th) | 4.4 (4.1,4.7) | 4.5 (4.1,4.7) | 4.4 (4.1,4.5) | 4.4 (4.2, 4.7) | 4.4 (4.2, 4.8) | 4.4 (4.1,4.5) |
| Platelets (x103/mm3) | n=93 | n=35 | n=55 | n=22 | ||
| Median (25th, 75th) | 197 (175, 234) | 194 (175, 240) | 200 (167, 226) | 201 (174, 251) | 226 (182, 263) | 198.5 (164, 220) |
| FIB-4 | n=91 | n=56 | n=35 | n=55 | n=22 | |
| Median (25th, 75th) | 1.4 (1.0, 1.9) | 1.4 (1.0, 1.7) | 1.5 (1.0, 2.2) | 1.3 (1.0, 1.9) | 1.2 (1.0, 1.6) | 1.8 (1.0, 2.2) |
| HBeAg, n (%) | ||||||
| Positive | 58 (61.1) | 58 (100.0) | 0 (0.0) | 33 (58.9) | 33 (100.0) | 0 (0.0) |
| HBeAg (log10 IU/mL) | n=94 | n=36 | n=55 | n=22 | ||
| Median (25th, 75th) | 0.1 (−0.7, 1.4) | 1.0 (0.1,2.1) | −0.9 (−1.1, −0.6) | 0.0 (−0.7, 1.2) | 0.4 (0.1, 1.7) | −0.8 (−1.1, −0.6) |
| HBsAg (log10 IU/mL) | n=94 | n=36 | n=55 | n=22 | ||
| Median (25th, 75th) | 3.2 (2.8, 3.8) | 3.4 (3.1,4.1) | 2.6 (1.9, 3.3) | 3.1 (2.5, 3.4) | 3.3 (3.1,3.8) | 2.2 (1.7, 3.1) |
| HBV DNA (log10 IU/mL) | ||||||
| Median (25th, 75th) | 1.2 (0.9, 1.8) | 1.3 (1.1,3.4) | 1.0 (0.8, 1.2) | 1.1 (0.9, 1.7) | 1.2 (1.0, 2.0) | 1.0 (0.8, 1.2) |
| CD4 (cells/mm3) | n=85 | n=53 | n=32 | n=52 | n=31 | n=21 |
| 567 | 567 | 567 | 560 | 516 | 574 | |
| Median (25th, 75th) | (369, 680) | (374, 680) | (354.5, 695.5) | (358.5, 672.5) | (343, 629) | (393, 718) |
| HIV RNA (copies/mL) | n=85 | n=53 | n=32 | n=50 | n=31 | n=19 |
| <20 | 68 (80.0) | 39 (73.6) | 29 (90.6) | 43 (86.0) | 25 (80.6) | 18 (94.7) |
| 20 – <400 | 13 (15.3) | 10 (18.9) | 3 (9.4) | 5 (10.0) | 4 (12.9) | 1 (5.3) |
| 400 – <10000 | 1 (1.2) | 1 (1.9) | 0 (0.0) | 1 (2.0) | 1 (3.2) | 0 (0.0) |
| ≥10000 | 3 (3.5) | 3 (5.7) | 0 (0.0) | 1 (2.0) | 1 (3.2) | 0 (0.0) |
| HBV DNA (IU/mL) and HIV | n=85 | n=53 | n=32 | n=50 | n=31 | n=19 |
| RNA (copies/mL) suppression status | ||||||
| Suppressed (HBV DNA <1000, HIV RNA <400) | 71 (83.5) | 39 (73.6) | 32 (100.0) | 43 (86.0) | 24 (77.4) | 19 (100.0) |
| Incompletely suppressed (HBV DNA ≥1000, HIV RNA <400) | 10 (11.8) | 10 (18.9) | 0 (0.0) | 5 (10.0) | 5 (16.1) | 0 (0.0) |
| Not suppressed (HBV DNA ≥1000, HIV RNA ≥400) | 4 (4.7) | 4 (7.5) | 0 (0.0) | 2 (4.0) | 2 (6.5) | 0 (0.0) |
| HBV RNA (log10 U/mL) | ||||||
| Median (25th, 75th) | 3.8 (1.8, 5.6) | 5.3 (3.9, 6.6) | 1.4 (0.1,2.2) | 3.5 (1.8, 5.5) | 4.8 (3.6, 6.4) | 1.8 (0.0, 2.5) |
| HBcrAg (log10 U/mL) | ||||||
| Median (25th, 75th) | 5.5 (3.4, 7.0) | 6.3 (5.5, 8.2) | 3.3 (1.9, 4.0) | 5.3 (3.7, 6.5) | 6.3 (5.4, 7.8) | 3.3 (1.9, 4.3) |
Accroymns: ALT, Alanine Aminotransferase; AST, Aspartate aminotransferase; CD4, Cluster of differentiation 4; DNA, Deoxyribonucleic acid; FIB-4, Fibrosis-4; HBcrAg, Hepatitis B core-related antigen; HBV, Hepatitis B virus; HCV, Hepatitis C virus; HDV, Hepatitis D virus; HIV, Human immunodeficiency virus; HBeAg, Hepatitis B e-antigen; HBsAg, Hepatitis B surface antigen; RNA, Ribonucleic acid.